Similar articles

• Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy.

  Micetich KC, Jensen-Akula M, Mandard JC, Fisher RI. Micetich KC, et al. Am J Med. 1981 Dec;71(6):967-72. doi: 10.1016/0002-9343(81)90315-6. Am J Med. 1981. PMID: 7032289 Clinical Trial.
• Interstitial pulmonary fibrosis as a complication of prolonged methyl-CCNU therapy.

  Lee W, Moore RP, Wampler GL. Lee W, et al. Cancer Treat Rep. 1978 Sep;62(9):1355-8. Cancer Treat Rep. 1978. PMID: 688278 No abstract available.
• Leukemia after adjuvant chemotherapy with semustine (methyl-CCNU)--evidence of a dose-response effect.

  Boice JD, Greene MH, Killen JY Jr, Ellenberg SS, Fraumeni JF Jr, Keehn RJ, McFadden E, Chen TT, Stablein D. Boice JD, et al. N Engl J Med. 1986 Jan 9;314(2):119-20. doi: 10.1056/NEJM198601093140214. N Engl J Med. 1986. PMID: 3941685 No abstract available.
• [Nitrosourea-induced lung diseases].

  Massin F, Coudert B, Foucher P, Lombard JN, Reybet-Degat O, Jeannin L, Camus P. Massin F, et al. Rev Mal Respir. 1992;9(6):575-82. Rev Mal Respir. 1992. PMID: 1470749 Review. French.
• [Clinical significance of mustoforan in management of malignant glioma].

  Kobiakov GL. Kobiakov GL. Vopr Onkol. 2007;53(6):724-9. Vopr Onkol. 2007. PMID: 18416147 Review. Russian. No abstract available.